Ann Monken
Family · Terre Haute, INNPI 1043724743
Payments from drug & device makers
Across 219 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$746
- AbbVie$626
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$459
- Lilly USA, LLC$422
- GSK$316
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,519100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,185 |
| Novo Nordisk | 31 | $746 |
| AbbVie | 35 | $626 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $459 |
| Lilly USA, LLC | 20 | $422 |
| GSK | 14 | $316 |
| Amgen | 10 | $248 |
| Axsome Therapeutics, Inc. | 4 | $193 |
| Idorsia Pharmaceuticals US Inc | 5 | $181 |
| Dexcom, Inc. | 7 | $140 |
| Bayer | 7 | $117 |
| Novartis | 5 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $113 |
| Exact Sciences | 5 | $87 |
| Boehringer Ingelheim | 4 | $80 |
| Corium, LLC | 3 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Abbott | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Pfizer | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,519 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $151,357 |
| FarxigaDapagliflozin Propanediol | 41 | $39,751 |
| MounjaroTirzepatide | 31 | $31,912 |
| JanuviaSitagliptin Phosphate | 24 | $29,597 |
| XareltoRivaroxaban | 26 | $28,682 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $27,687 |
| TrulicityDulaglutide | 15 | $24,090 |
| EliquisApixaban | 19 | $23,304 |
| JardianceEmpagliflozin | 14 | $15,690 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $13,047 |
| NamzaricMemantine Hcl/Donepezil Hcl | 19 | $12,506 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $10,954 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,591 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,732 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $7,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $746 | $151,357107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $422 | $56,00246 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $316 | $46,99891 claims |
| AstraZenecaFarxiga | $1,185 | $39,75141 claims |
| MerckJanuvia, Janumet | $14 | $37,32938 claims |
| Johnson & JohnsonXarelto | $18 | $28,68226 claims |
| PfizerEliquis | $28 | $23,30419 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $80 | $22,79727 claims |
| AbbVieNamzaric, Synthroid | $626 | $14,26851 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $3,043390 claims |
| Sanofi-aventis U.S. LLCLantus | $34 | $2,18411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.